Melanoma Clinical Trials in Houston

Showing 181-200 of 268 trials

Biochemotherapy With Temozolomide for Metastatic Melanoma

NCT00505635

The goal of this clinical research study is to learn if treatment with Temodar (temozolomide), Velban (vinblastine), Cisplatin, Proleukin (interleukin-2), Intron-A (interferon alpha), and thalidomide can help to control melanoma that has spread to other parts of the body. The safety of this treatment will also be studied.

Melanoma

M.D. Anderson Cancer Center5 participantsStarted Mar 2007

Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

NCT00525031

The goal of this clinical research study is to learn if temozolomide alone or given with pegylated interferon alpha-2b can help to control metastatic melanoma. Researchers also want to study the safety of these 2 treatments. Objectives: 1. To determine the anti-tumor activity (pathological response CR+PR) and toxicity of temozolomide (TMZ) alone or in combination with pegylated interferon alpha-2b (PGI) in patients with resectable stage IIIC or stage IV (M1a) metastatic melanoma prior to definitive surgical resection. 2. To determine the relapse-free survival, overall survival and the impact of tumor response to chemotherapy in these patients. 3. To differentiate the in vivo treatment effects of TMZ alone vs.TMZ plus PGI and correlate with clinical outcome by analysis the pre- and post-treatment tumors and peripheral blood mononuclear cells with respect to: 1\) Known cellular and molecular markers of apoptosis and cell proliferation, 2) Promotor methylation status of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT), 3) DNA sequence variability of tumor suppressor genes and DNA repair enzymes, 4) Tumor genomic expression profiles analysis by complementary DNA (cDNA) microarray and protein array

Melanoma

M.D. Anderson Cancer Center55 participantsStarted Aug 2006

Houston, Texas, United States

Biochemotherapy With Temozolomide for Metastatic Melanoma

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Melanoma Trials in Other Cities

Melanoma Risk-Reduction Among Patients and Family Members

Doxycycline, Temozolomide and Ipilimumab in Melanoma

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Other Conditions in Houston